This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy and Cookie Notice.

Skip to main content

Search Results

Featured Stories

Toggle

Christoph Stoller Appointed as new President of Medicines for Europe

Republished with permission from Medicines for Europe - 25 September, 2019 Immediately calls on new President of EU Commission to prioritise Healthcare Christoph Stoller (General Manager...

Building a Balanced Future for Generics

Teva's Brendan O'Grady takes the stage at AAM Annual Meeting. Teva’s Executive Vice President and head of North America Commercial, Brendan O’ Grady, recently took the stage alongside industry...

2017 Annual Report now available

On February 8, 2018, we reported Teva's financial results for Q4 and full year 2017, and provided the outlook for 2018. Kåre Schultz, Teva’s President and CEO, said, “2017 was a challenging year fo...

Restructuring to simplify our business: JP Morgan highlights

Sharing our story at the largest healthcare conference. In early January, Teva President & CEO Kåre Schultz spoke at the J.P. Morgan 36th Annual Healthcare Conference in San Francisco. He reviewed...

Teva Announces Virtual 2020 Annual Meeting of Shareholders

TEL AVIV, Israel--( BUSINESS WIRE )-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders,...

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab

TEL AVIV, Israel--( BUSINESS WIRE )-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY ® (fremanezumab) and the societal and economic...